Previous 10 | Next 10 |
Theravance Biopharma to Participate in Upcoming Investor Conferences PR Newswire DUBLIN , Feb. 10, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and com...
Theravance Biopharma to Report Fourth Quarter and Full Year 2020 Financial Results on February 23, 2021 PR Newswire DUBLIN , Feb. 9, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused...
Theravance Biopharma To Present at the 39th Annual J.P. Morgan Healthcare Conference PR Newswire DUBLIN , Jan. 5, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, developme...
Today, we revisit Theravance Biopharma for the first time in over a year. The stock has had a challenging year in 2020, but there are some potentially significant catalysts on the horizon in 2021. We update our investment thesis in full on Theravance in the paragraphs below. ...
Theravance Biopharma to Present at the 3rd Annual Evercore ISI HEALTHCONx Conference PR Newswire DUBLIN, Nov. 17, 2020 DUBLIN , Nov. 17, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily foc...
Seth Klarman’s 13F portfolio value increased from $8.01B to $9.25B this quarter. Baupost Group added Pershing Square Tontine, Micron Technology, and Applied Materials while dropping Akebia Therapeutics. The portfolio continues to be heavily concentrated with the top three p...
Theravance Biopharma, Inc. (TBPH) Q3 2020 Earnings Conference Call November 5, 2020 5:00 PM ET Company Participants Gail Cohen - Vice President, Corporate Communications and Investor Relations Rick Winningham - Chief Executive Officer Frank Pasqualone - Chief Commercial Operations Officer Bre...
Image source: The Motley Fool. Theravance Biopharma Inc (NASDAQ: TBPH) Q3 2020 Earnings Call Nov 6, 2020 , 5:00 p.m. ET Operator Continue reading For further details see: Theravance Biopharma Inc (TBPH) Q3 2020 Earnings Call Transcript
The following slide deck was published by Theravance Biopharma, Inc. in conjunction with their 2020 Q3 earnings call. For further details see: Theravance Biopharma, Inc. 2020 Q3 - Results - Earnings Call Presentation
Theravance Biopharma (TBPH): Q3 GAAP EPS of -$1.16 misses by $0.15.Revenue of $18.26M (+46.9% Y/Y) misses by $0.32M.Press Release For further details see: Theravance Biopharma EPS misses by $0.15, misses on revenue
News, Short Squeeze, Breakout and More Instantly...
Theravance Biopharma Inc. Company Name:
TBPH Stock Symbol:
NASDAQ Market:
Theravance Biopharma Inc. Website:
2024-06-15 00:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire Q1 2024 YUPELRI ® (revefenacin) net sales of $55.2 million , recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboratio...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...